Fig. 3.

HRQoL: a EQ-VAS and b EQ-5D HSV adjusted least square mean (SE) change from baseline. Data presented are from MMRM analyses. Models included change from baseline in EQ-VAS or EQ-5D HSV as dependent variable, visit as a fixed repeated effect, and baseline score (EQ-VAS or EQ-5D HSV), age, duration of prior bisphosphonate therapy, number of previous fractures, fractures in the 12 months before starting teriparatide and diagnosis of rheumatoid arthritis or other rheumatological disorder as covariates. *p < 0.0001 compared with baseline. The mean (SD) EQ-VAS values at baseline 3, 6, 12, 18 and 24 months were 56.6 (21.2), 61.8 (19.6), 64.8 (19.9), 67.8 (19.1), 69.4 (19.1) and 72.3 (19.7), respectively. The mean (SD) EQ-5D HSV scores at baseline 3, 6, 12, 18 and 24 months were 0.50 (0.36), 0.63 (0.30), 0.68 (0.27), 0.70 (0.27), 0.74 (0.25) and 0.76 (0.24), respectively